Ceftolozane/tazobactam: Phase III data

Last month, Cubist reported that IV ceftolozane/tazobactam met the FDA- and EMA-defined primary endpoints of non-inferiority to IV levofloxacin in a pair of identical Phase III trials to treat complicated urinary tract infection (cUTI) (see BioCentury, Dec. 9). Cubist plans to submit an NDA to

Read the full 455 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE